BAP1 rewires cell surfaces to reduce Parkinson's protein entry.

In Parkinson’s disease, clumps of a protein called alpha-synuclein spread between brain cells, making the illness worse over time. Scientists wanted to find out how cells take in these toxic clumps. They used a gene-activating tool called CRISPRa across the entire genome to search for helpful genes. They discovered that a gene called BAP1 slows down this uptake. Inside cells, BAP1 changes the proteins and sugars on the cell surface. It lowers molecules called heparan sulfate proteoglycans and boosts O-linked glycoproteins. Together, these surface shifts block the clumps from entering. This defense works specifically in dopamine-producing brain cells, but not in immune cells called microglia. In lab-grown brain tissue, BAP1 teams up with another risk gene, ASXL3, to protect cells. Brain areas that naturally have more of both genes show greater resistance to Parkinson's disease damage.

Why it matters

Parkinson's disease progresses as toxic protein aggregates spread between brain cells. This work reveals a molecular switch that controls whether those aggregates get inside cells, and it works differently in different cell types. That difference might explain why some brain regions are more vulnerable than others, and could point toward new ways to slow the disease.

Questions answered